Bank of New York Mellon Corp vs Novavax Inc — how do they compare? Bank of New York Mellon Corp trades at $163.67 (market cap $108.78B), while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: Bank of New York Mellon Corp is far larger — about 83× Novavax Inc's market cap, and Bank of New York Mellon Corp pays a 1.38% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| BNY | NVAX | |
|---|---|---|
Market Cap | $108.78B | $1.31B |
Sector | Financials | Health |
52-Week High | $162.35 | $11.19 |
52-Week Low | $101.00 | $6.22 |
Dividend Yield | 1.38% | — |
Enterprise Value | — | $889.30M |
Signals from Pluang's Aura AI — not financial advice
BNY stock trades at $162.98, up 2.22% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported record Q2 2026 results with EPS of $2.46, surpassing estimates, and announced a strategic collaboration to advance digital asset infrastructure. Revenue growth is steady, rising to $19.76B in 2025, with a net income margin of 29.96%.
Outlook remains positive with a consensus price target of $170.36, though risks include high investing cash outflows and competitive pressures. The stock's current price is near the consensus target, suggesting limited upside without further catalysts. Institutional sentiment is mixed, with 45% buy ratings and 55% hold.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Trailing returns across standard periods
Latest headlines on both assets
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →